News
Earlier use of Chantix may ease quitting
-
Print -
Comments
-
“Whether through changes in taste or nausea, it seems this extra varenicline reduces smoking rates before people try to quit.”
Smokers planning to kick the habit may have more success if they begin using a cessation medication several weeks before they actually try to quit, according to results of a clinical trial conducted by researchers at UB, Roswell Park Cancer Institute (RPCI) and other institutions.
The study recently was published in Clinical Pharmacology and Therapeutics.
The study focused on 35 women and 25 men, all smokers from Western New York who were, on average, 48 years old and smoked a pack of cigarettes a day. Participants who took the smoking cessation medication varenicline (marketed as Chantix) for four weeks prior to trying to quit smoking were more likely to successfully quit smoking than those who took varenicline for just one week before quitting—the current standard therapy for the drug. Everyone took the medication for an additional 11 weeks after the quit day.
“Varenicline was designed to make smoking less rewarding and our data suggests that it does that better when people take it for a few extra weeks before quitting,” says Larry W. Hawk Jr., lead author and associate professor in the Department of Psychology, College of Arts and Sciences. “If this finding holds up in larger studies, it could have a major impact on public health.”
“We saw nearly full compliance, which suggests that this is not only a well-tolerated therapy, but one people can realistically stick with,” says co-author Martin C. Mahoney, associate professor of oncology in RPCI’s departments of Medicine and Health Behavior, and clinical associate professor in the UB schools of Public Health and Health Professions and Medicine and Biomedical Sciences.
While Mahoney says many participants reported mild nausea, the symptoms typically dissipated after a couple of weeks and may have helped reduce their desire to smoke.
“Whether through changes in taste or nausea, it seems this extra varenicline reduces smoking rates before people try to quit,” Hawk says. “These changes should make it easier to quit smoking, but we also know that it takes some period of time for this new learning to occur. That’s why we decided to see if a longer period of treatment with varenicline before smokers tried to quit would result in better outcomes, and it did in this small study.”
Of special interest was the fact that women who took varenicline for four weeks were especially likely to reduce their smoking, possibly because they reported more nausea in the pre-quit period. After three weeks of treatment with varenicline, women reduced their smoking by more than 50 percent, on average. The men who took the varenicline for four weeks reduced their smoking by 26 percent. The researchers say that much larger studies are needed to tell whether the gender differences are real.
“This study suggests we may be able to take the most effective smoking-cessation treatment we have and make it work 50 percent better just by giving the medication for a few weeks before smokers attempt to quit,” concludes Hawk.
In addition to Hawk and Mahoney, co-authors are Rebecca L. Ashare, Nicolas J. Schlienz, Stephen T. Tiffany, Julie C. Gass and Jessica D. Rhodes, all of the Department of Psychology; Shaun Fickling Lohnes of RPCI; and K. Michael Cummings, former chair of the Department of Health Behavior at RPCI who now is at the Medical University of South Carolina.
The study was funded in part by a 2008 Global Research Award for Nicotine Dependence (GRAND), an independent, investigator-initiated research program sponsored by Pfizer, which manufactures varenicline, and by the National Institute for Drug Abuse.
Reader Comments